Torrent Sees Fortunes Affected By Regulatory Overhang
Dahej Unit Heads For Re-inspection By Mid-2020
Torrent has tempered FY21 US growth expectations while it plans to put Dahej, Indrad and Levittown plants up for FDA inspection in 2020. Meanwhile, products launched in India, including remoglifozin in-licensed from Glenmark, have shown an encouraging uptake.
You may also be interested in...
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.
Warning letter stemming from global nitrosamine investigation raises new concerns about Indian manufacturer.